Katlin Brauer Massirer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katlin Brauer Massirer has a total of 318 co-authors. Here are the top co-authors by number of shared publications:
- Rafael Miguez Counago
Center of Medicinal Chemistry Center for Molecular Biology and Genetic Engineering Universidade Estadual de Campinas Av. Dr. André Tosello 550 Campinas 13083-886 Brazil
14 shared publications - Jonathan M. Elkins
University of Oxford
8 shared publications - Micael Rodrigues Cunha
Center of Medicinal Chemistry Center for Molecular Biology and Genetic Engineering Universidade Estadual de Campinas Av. Dr. André Tosello 550 Campinas 13083-886 Brazil
7 shared publications - André da Silva Santiago
Universidade Estadual de Campinas
6 shared publications - Caio dos Reis
Universidade Estadual de Campinas (UNICAMP)
5 shared publications - Jessica E. Takarada
Center of Medicinal Chemistry Center for Molecular Biology and Genetic Engineering Universidade Estadual de Campinas Av. Dr. André Tosello 550 Campinas 13083-886 Brazil
5 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by Wiley in FASEB BioAdvances
- Vol. 8 (8) , e70135
Exploring the BICC1 Interactome in HEK293T Cells: Insights Into RNA ‐Mediated Protein Networks and Biomolecular Condensates
Bicaudal C Homolog 1 (BICC1) is a conserved RNA‐binding protein that, in mammals, has been primarily associated with polycystic kidney disease and renal organogenesis. However, its role in other disease contexts, including cancer, remains poorly understood. In this study, we characterized the BICC1 interactome, with emphasis on its dependence on RNA and the sterile alpha motif (SAM) domain, to identify novel biological processes associated with BICC1 function. Protein complexes were purified from HEK293T cells by co‐immunoprecipitation and analyzed by mass spectrometry. Notably, co‐immunoprecipitations performed in the presence of RNA yielded a larger number of interacting proteins, with 31 of 71 proteins (~43%) uniquely identified under RNA‐preserved conditions, highlighting the critical role of RNA in mediating BICC1 protein–protein interactions. Enriched proteins were predominantly associated with mRNA splicing, the PRMT5 methylosome complex, and membraneless organelles, such as biomolecular condensates. Consistent with these findings, immunofluorescence assays performed on stressed cells revealed the co‐localization of BICC1 with stress granule markers. Moreover, BICC1 interactions with PRMT5, STK38, PARP1, and IGF2BP1 were confirmed by immunoblotting.
- 7 August 2026
- Published by Wiley in FASEB BioAdvances
- Vol. 8 (8) , e70135
Open AccessExploring the BICC1 Interactome in HEK293T Cells: Insights Into RNA ‐Mediated Protein Networks and Biomolecular Condensates
Bicaudal C Homolog 1 (BICC1) is a conserved RNA‐binding protein that, in mammals, has been primarily associated with polycystic kidney disease and renal organogenesis. However, its role in other disease contexts, including cancer, remains poorly understood. In this study, we characterized the BICC1 interactome, with emphasis on its dependence on RNA and the sterile alpha motif (SAM) domain, to identify novel biological processes associated with BICC1 function. Protein complexes were purified from HEK293T cells by co‐immunoprecipitation and analyzed by mass spectrometry. Notably, co‐immunoprecipitations performed in the presence of RNA yielded a larger number of interacting proteins, with 31 of 71 proteins (~43%) uniquely identified under RNA‐preserved conditions, highlighting the critical role of RNA in mediating BICC1 protein–protein interactions. Enriched proteins were predominantly associated with mRNA splicing, the PRMT5 methylosome complex, and membraneless organelles, such as biomolecular condensates. Consistent with these findings, immunofluorescence assays performed on stressed cells revealed the co‐localization of BICC1 with stress granule markers. Moreover, BICC1 interactions with PRMT5, STK38, PARP1, and IGF2BP1 were confirmed by immunoblotting.
- Open Access
Bordetella pertussis BctCBA Mediates Citrate-Dependent Zn 2+ and Ni 2+ binding
Bordetella pertussis , the causative agent of whooping cough, is a reemerging public health threat. While the Tripartite Tricarboxylate Transporter (TTT) system BctCBA was previously implicated solely in citrate uptake, we demonstrate that the solute-binding protein BctC specifically binds citrate chelated with Zn²⁺ and Ni²⁺. To elucidate the molecular mechanism of this interaction, we determined the crystal structures of BctC in three states: apo, open, and closed (citrate–zinc-bound), defining the structural determinants for metal-citrate recognition. Comparative analyses suggest that citrate-mediated divalent cation binding is a widespread feature among bacterial TTT homologs. Finally, in silico modeling of the full BctCBA complex predicts an elevator-type transport mechanism. Together, these findings redefine the functional scope of BctCBA, revealing a sophisticated strategy by which B. pertussis exploits organic chelators to acquire essential trace metals during infection.
Open AccessBordetella pertussis BctCBA Mediates Citrate-Dependent Zn 2+ and Ni 2+ binding
Bordetella pertussis , the causative agent of whooping cough, is a reemerging public health threat. While the Tripartite Tricarboxylate Transporter (TTT) system BctCBA was previously implicated solely in citrate uptake, we demonstrate that the solute-binding protein BctC specifically binds citrate chelated with Zn²⁺ and Ni²⁺. To elucidate the molecular mechanism of this interaction, we determined the crystal structures of BctC in three states: apo, open, and closed (citrate–zinc-bound), defining the structural determinants for metal-citrate recognition. Comparative analyses suggest that citrate-mediated divalent cation binding is a widespread feature among bacterial TTT homologs. Finally, in silico modeling of the full BctCBA complex predicts an elevator-type transport mechanism. Together, these findings redefine the functional scope of BctCBA, revealing a sophisticated strategy by which B. pertussis exploits organic chelators to acquire essential trace metals during infection.
- Open Access
Genes/variants for diagnostic testing and pre-clinical research in autism spectrum disorder
Purpose: Genetic discoveries have provided etiological insight into autism spectrum disorder (ASD) such that genetic testing has become standard of care. To date, consensus about which genes are robustly associated with autism liability, and which are not, is inconsistent. Consequently, different curated ASD gene lists are applied in diagnostic testing, pre-clinical model development, and the design of precision therapeutics. Methods: We address this issue using the Evaluation of Autism Gene Link Evidence (EAGLE) framework, which allows for a protocolized and replicable curation of genes. Additionally, we compared the functional- and expression- characteristics of EAGLE-curated genes. Results: We curated 222 genes and found 78 genes with definitive EAGLE-evidence for association with autism: 43 with moderate evidence, and 99 with limited evidence for a role in ASD (noting all 222 genes are associated with the broader category of neurodevelopmental disorders (NDDs)). The top 10 EAGLE-scoring genes are NRXN1-SCN2A-MECP2-CHD8-RNU4-2-DDX3X-SHANK3-PTEN-FOXP1 , and MBD5 . Conclusion: EAGLE allows curation of evidence for association of genes with autism, as opposed to with NDDs broadly. Our analysis also revealed differential patterns of enrichment and expression profiles at the brain and cellular level, suggesting the biological relevance of differentiating ASD and the broader NDD-phenotype.
Open AccessGenes/variants for diagnostic testing and pre-clinical research in autism spectrum disorder
Purpose: Genetic discoveries have provided etiological insight into autism spectrum disorder (ASD) such that genetic testing has become standard of care. To date, consensus about which genes are robustly associated with autism liability, and which are not, is inconsistent. Consequently, different curated ASD gene lists are applied in diagnostic testing, pre-clinical model development, and the design of precision therapeutics. Methods: We address this issue using the Evaluation of Autism Gene Link Evidence (EAGLE) framework, which allows for a protocolized and replicable curation of genes. Additionally, we compared the functional- and expression- characteristics of EAGLE-curated genes. Results: We curated 222 genes and found 78 genes with definitive EAGLE-evidence for association with autism: 43 with moderate evidence, and 99 with limited evidence for a role in ASD (noting all 222 genes are associated with the broader category of neurodevelopmental disorders (NDDs)). The top 10 EAGLE-scoring genes are NRXN1-SCN2A-MECP2-CHD8-RNU4-2-DDX3X-SHANK3-PTEN-FOXP1 , and MBD5 . Conclusion: EAGLE allows curation of evidence for association of genes with autism, as opposed to with NDDs broadly. Our analysis also revealed differential patterns of enrichment and expression profiles at the brain and cellular level, suggesting the biological relevance of differentiating ASD and the broader NDD-phenotype.
- 25 September 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (10) , 2859-2870
Discovery and Characterization of Cell-Permeable Inhibitors of Leishmania mexicana CLK1 Using an In-Cell Target Engagement Assay
Leishmaniasis is a neglected tropical disease with limited treatment options and significant unmet medical need. Here, we report the development of a bioluminescence resonance energy transfer (BRET)-based target engagement assay in live cells to identify and validate cell-permeable, ATP-competitive inhibitors of Leishmania mexicana (Lmx)CLK1. LmxCLK2, a closely related paralog with an identical protein kinase domain, is also considered in our analysis. Genetic and pharmacological evidence indicates that simultaneous deletion or inhibition of both LmxCLK1/2 is lethal to the parasite. Using our newly developed assay, we screened a library of human kinase inhibitors and identified WZ8040, a third-generation EGFR inhibitor, as a potent LmxCLK1 ligand. WZ8040 demonstrated robust target engagement in both promastigotes and macrophage-internalized amastigotes, with an EC50 value of 2.1 μM for amastigote killing and minimal toxicity to host macrophages. Biochemical assays confirmed that WZ8040 covalently binds and inhibits LmxCLK1, with mass spectrometry identifying Cys172 as the primary site of modification. Genetic validation using overexpression and knockout lines supports LmxCLK1 as the primary target of WZ8040. However, the retained activity of WZ8040 in mutant lines with the Cys172Ala substitution suggests that covalent binding is not essential for compound efficacy. Our findings highlight the utility of BRET-based assays for target validation in kinetoplastid parasites and underscore the potential of CLK1/2 as druggable kinases in Leishmania. This integrated approach provides a framework for accelerating the discovery of novel antileishmanial agents through target engagement-guided strategies.
- 25 September 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (10) , 2859-2870
Discovery and Characterization of Cell-Permeable Inhibitors of Leishmania mexicana CLK1 Using an In-Cell Target Engagement Assay
Leishmaniasis is a neglected tropical disease with limited treatment options and significant unmet medical need. Here, we report the development of a bioluminescence resonance energy transfer (BRET)-based target engagement assay in live cells to identify and validate cell-permeable, ATP-competitive inhibitors of Leishmania mexicana (Lmx)CLK1. LmxCLK2, a closely related paralog with an identical protein kinase domain, is also considered in our analysis. Genetic and pharmacological evidence indicates that simultaneous deletion or inhibition of both LmxCLK1/2 is lethal to the parasite. Using our newly developed assay, we screened a library of human kinase inhibitors and identified WZ8040, a third-generation EGFR inhibitor, as a potent LmxCLK1 ligand. WZ8040 demonstrated robust target engagement in both promastigotes and macrophage-internalized amastigotes, with an EC50 value of 2.1 μM for amastigote killing and minimal toxicity to host macrophages. Biochemical assays confirmed that WZ8040 covalently binds and inhibits LmxCLK1, with mass spectrometry identifying Cys172 as the primary site of modification. Genetic validation using overexpression and knockout lines supports LmxCLK1 as the primary target of WZ8040. However, the retained activity of WZ8040 in mutant lines with the Cys172Ala substitution suggests that covalent binding is not essential for compound efficacy. Our findings highlight the utility of BRET-based assays for target validation in kinetoplastid parasites and underscore the potential of CLK1/2 as druggable kinases in Leishmania. This integrated approach provides a framework for accelerating the discovery of novel antileishmanial agents through target engagement-guided strategies.
- Open Access
Synthesis of 6-Arylaminoflavones via Buchwald–Hartwig Amination and Its Anti-Tumor Investigation
A new series of 6-arylaminoflavones was synthesized via the Buchwald–Hartwig cross-coupling reaction, aiming to functionalize the flavone core efficiently. Reaction optimization revealed that Pd2(dba)3/XantPhos with Cs2CO3 in toluene provided the best yields, with isolated yields ranging from 8% to 95%, depending on the arylamine structure. Steric hindrance and electron-withdrawing groups at the arylamine ring impacted the reaction outcomes. Cytotoxicity assays in different human cancer cell lines indicated that substitution patterns at both the arylamine and B-rings strongly impacted biological activity. In particular, compounds bearing a 3,4-dimethoxy substitution at the B-ring and a trifluoromethyl (13c) or chlorine (13g) group at the aniline moiety exhibited enhanced cytotoxicity. These findings provide insights into the structure–activity relationship of 6-arylaminoflavones while contributing to the development of synthetic methodologies for functionalized flavones.
Open AccessSynthesis of 6-Arylaminoflavones via Buchwald–Hartwig Amination and Its Anti-Tumor Investigation
A new series of 6-arylaminoflavones was synthesized via the Buchwald–Hartwig cross-coupling reaction, aiming to functionalize the flavone core efficiently. Reaction optimization revealed that Pd2(dba)3/XantPhos with Cs2CO3 in toluene provided the best yields, with isolated yields ranging from 8% to 95%, depending on the arylamine structure. Steric hindrance and electron-withdrawing groups at the arylamine ring impacted the reaction outcomes. Cytotoxicity assays in different human cancer cell lines indicated that substitution patterns at both the arylamine and B-rings strongly impacted biological activity. In particular, compounds bearing a 3,4-dimethoxy substitution at the B-ring and a trifluoromethyl (13c) or chlorine (13g) group at the aniline moiety exhibited enhanced cytotoxicity. These findings provide insights into the structure–activity relationship of 6-arylaminoflavones while contributing to the development of synthetic methodologies for functionalized flavones.
- Open Access
- 18 July 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (8) , 2736-2755
Hit-to-Lead Studies of Pyrazinylpiperazines against Visceral Leishmaniasis: Pharmacokinetic Profile and In Vivo Efficacy of Potent Compounds against Leishmania infantum
As part of the hit-to-lead optimization of antileishmanial pyrazinylpiperazines, the Absorption, Distribution, Metabolism, and Excretion (ADME) properties of the initial hit and five candidates for in vivo studies were assessed in vitro. These candidates, which displayed improved potency against Leishmania infantum (IC50 < 5 μM), were selected from an earlier structure–activity relationship study. Such assessment revealed that, except for the catechol derivative 6, all derivatives exhibited an improved overall ADME profile in comparison to the initial hit. The para-hydroxyl analog 2 stood out as the most promising candidate, being the second most potent compound in vitro against the parasite and showing far superior metabolic stability (more than twice as stable as the initial hit) in mouse liver microsomes, together with a reasonable gastrointestinal absorption and a lack of blood–brain barrier permeation. In vivo assessment of the antileishmanial efficacy of 2 in a BALB/c mice model of visceral leishmaniasis revealed a reduction in parasitemia by 91.1 and 90.0% in the spleen and liver, respectively, after a 10 day treatment of infected animals with a 100 mg/kg daily dose of 2, without any acute toxicity or death among mice treated with 2. Flow cytometry demonstrated that the antileishmanial activity of 2 is linked to a cytostatic effect, marked by cell cycle arrest in the G0/G1 phase and enhanced production of reactive oxygen species. Subsequent in silico studies suggested that the activity of the novel antileishmanial pyrazinylpiperazine lead 2 could be due to the inhibition of a nonspecific serine/threonine protein kinase in Leishmania infantum; however, in vitro inhibition assays failed to identify a target for 2 among a set of kinases and other proteins.
- 18 July 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (8) , 2736-2755
Open AccessHit-to-Lead Studies of Pyrazinylpiperazines against Visceral Leishmaniasis: Pharmacokinetic Profile and In Vivo Efficacy of Potent Compounds against Leishmania infantum
As part of the hit-to-lead optimization of antileishmanial pyrazinylpiperazines, the Absorption, Distribution, Metabolism, and Excretion (ADME) properties of the initial hit and five candidates for in vivo studies were assessed in vitro. These candidates, which displayed improved potency against Leishmania infantum (IC50 < 5 μM), were selected from an earlier structure–activity relationship study. Such assessment revealed that, except for the catechol derivative 6, all derivatives exhibited an improved overall ADME profile in comparison to the initial hit. The para-hydroxyl analog 2 stood out as the most promising candidate, being the second most potent compound in vitro against the parasite and showing far superior metabolic stability (more than twice as stable as the initial hit) in mouse liver microsomes, together with a reasonable gastrointestinal absorption and a lack of blood–brain barrier permeation. In vivo assessment of the antileishmanial efficacy of 2 in a BALB/c mice model of visceral leishmaniasis revealed a reduction in parasitemia by 91.1 and 90.0% in the spleen and liver, respectively, after a 10 day treatment of infected animals with a 100 mg/kg daily dose of 2, without any acute toxicity or death among mice treated with 2. Flow cytometry demonstrated that the antileishmanial activity of 2 is linked to a cytostatic effect, marked by cell cycle arrest in the G0/G1 phase and enhanced production of reactive oxygen species. Subsequent in silico studies suggested that the activity of the novel antileishmanial pyrazinylpiperazine lead 2 could be due to the inhibition of a nonspecific serine/threonine protein kinase in Leishmania infantum; however, in vitro inhibition assays failed to identify a target for 2 among a set of kinases and other proteins.
- Open Access
Discovery and characterization of cell-permeable inhibitors of Leishmania mexicana CLK1 using an in-cell target engagement assay
Leishmaniasis is a neglected tropical disease with limited treatment options and significant unmet medical need. Here, we report the development of a bioluminescence resonance energy transfer (BRET)-based target engagement assay in live intact cells to identify and validate cell-permeable, ATP-competitive inhibitors of Leishmania mexicana (Lmx)CLK1. LmxCLK2, a closely related paralogue with an identical protein kinase domain, is also considered in our analysis. Genetic and pharmacological evidence indicates that simultaneous deletion or inhibition of both LmxCLK1/2 is lethal to the parasite. Using our newly developed assay, we screened a library of human kinase inhibitors and identified WZ8040, a third-generation EGFR inhibitor, as a potent LmxCLK1 ligand. WZ8040 demonstrated robust target engagement in both promastigotes and macrophage-internalized amastigotes, with low micromolar EC₅₀ values for parasite killing and minimal toxicity to host macrophages. Biochemical assays confirmed that WZ8040 covalently binds and inhibits LmxCLK1, with mass spectrometry identifying Cys172 as the primary site of modification. Genetic validation using overexpression and knockout lines supports LmxCLK1 as the primary target of WZ8040. However, the retained activity of WZ8040 in mutant lines with the Cys172Ala substitution suggests that covalent binding is not essential for compound efficacy. Our findings highlight the utility of BRET-based assays for target validation in kinetoplastid parasites and underscore the potential of CLK1 as a druggable kinase in Leishmania . This integrated approach provides a framework for accelerating the discovery of novel anti-leishmanial agents through target engagement-guided strategies. Highlights: - A live-cell NanoBRET assay enables in situ target engagement of CLK1 in Leishmania mexicana . - The covalent inhibitor WZ8040 effectively targets LmxCLK1 in both promastigote and intracellular amastigote stages. - CLK1 inhibition by WZ8040 does not depend on covalent modification of a single cysteine residue. - Combined target engagement and phenotypic data support LmxCLK1 as a druggable kinase in Leishmania .
Open AccessDiscovery and characterization of cell-permeable inhibitors of Leishmania mexicana CLK1 using an in-cell target engagement assay
Leishmaniasis is a neglected tropical disease with limited treatment options and significant unmet medical need. Here, we report the development of a bioluminescence resonance energy transfer (BRET)-based target engagement assay in live intact cells to identify and validate cell-permeable, ATP-competitive inhibitors of Leishmania mexicana (Lmx)CLK1. LmxCLK2, a closely related paralogue with an identical protein kinase domain, is also considered in our analysis. Genetic and pharmacological evidence indicates that simultaneous deletion or inhibition of both LmxCLK1/2 is lethal to the parasite. Using our newly developed assay, we screened a library of human kinase inhibitors and identified WZ8040, a third-generation EGFR inhibitor, as a potent LmxCLK1 ligand. WZ8040 demonstrated robust target engagement in both promastigotes and macrophage-internalized amastigotes, with low micromolar EC₅₀ values for parasite killing and minimal toxicity to host macrophages. Biochemical assays confirmed that WZ8040 covalently binds and inhibits LmxCLK1, with mass spectrometry identifying Cys172 as the primary site of modification. Genetic validation using overexpression and knockout lines supports LmxCLK1 as the primary target of WZ8040. However, the retained activity of WZ8040 in mutant lines with the Cys172Ala substitution suggests that covalent binding is not essential for compound efficacy. Our findings highlight the utility of BRET-based assays for target validation in kinetoplastid parasites and underscore the potential of CLK1 as a druggable kinase in Leishmania . This integrated approach provides a framework for accelerating the discovery of novel anti-leishmanial agents through target engagement-guided strategies. Highlights: - A live-cell NanoBRET assay enables in situ target engagement of CLK1 in Leishmania mexicana . - The covalent inhibitor WZ8040 effectively targets LmxCLK1 in both promastigote and intracellular amastigote stages. - CLK1 inhibition by WZ8040 does not depend on covalent modification of a single cysteine residue. - Combined target engagement and phenotypic data support LmxCLK1 as a druggable kinase in Leishmania .
- Open Access
Fragment Screening by Weak Affinity Chromatography Identifies Ligands for Neisseria gonorrhoeae Undecaprenyl Diphosphate Synthase
The rapid rise of antimicrobial resistance in Neisseria gonorrhoeae underscores the urgent need for new therapeutic strategies. Undecaprenyl diphosphate synthase (UPPS), an essential enzyme in bacterial cell wall biosynthesis, has emerged as a promising antimicrobial target. However, no structural information has been available for the gonococcal enzyme ( Ng UPPS), and known ligand scaffolds remain limited, hindering structure-based drug discovery efforts. Here, we present a combined weak affinity chromatography–mass spectrometry (WAC-MS) and crystallographic pipeline to identify and structurally characterize fragment binders of Ng UPPS. WAC-MS screening of a diverse fragment library identified 23 putative binders, 16 of which were successfully co- crystallized with Ng UPPS, primarily via soaking into preformed apo crystals. The resulting high-resolution structures mapped fragment binding across four distinct regions of the enzyme’s hydrophobic tunnel, encompassing the pyrophosphate- binding pockets and the distal product-binding site. Additionally, we determined the co-crystal structure of Ng UPPS with BPH-1100 , a known phthalic acid–based UPPS inhibitor, revealing that the enzyme adopts an open, ligand-competent conformation without significant rearrangement. Our results validate Ng UPPS as a structurally tractable antibacterial target and provide a strong foundation for fragment-based optimization and the future development of novel inhibitors to combat drug-resistant N. gonorrhoeae .
Open AccessFragment Screening by Weak Affinity Chromatography Identifies Ligands for Neisseria gonorrhoeae Undecaprenyl Diphosphate Synthase
The rapid rise of antimicrobial resistance in Neisseria gonorrhoeae underscores the urgent need for new therapeutic strategies. Undecaprenyl diphosphate synthase (UPPS), an essential enzyme in bacterial cell wall biosynthesis, has emerged as a promising antimicrobial target. However, no structural information has been available for the gonococcal enzyme ( Ng UPPS), and known ligand scaffolds remain limited, hindering structure-based drug discovery efforts. Here, we present a combined weak affinity chromatography–mass spectrometry (WAC-MS) and crystallographic pipeline to identify and structurally characterize fragment binders of Ng UPPS. WAC-MS screening of a diverse fragment library identified 23 putative binders, 16 of which were successfully co- crystallized with Ng UPPS, primarily via soaking into preformed apo crystals. The resulting high-resolution structures mapped fragment binding across four distinct regions of the enzyme’s hydrophobic tunnel, encompassing the pyrophosphate- binding pockets and the distal product-binding site. Additionally, we determined the co-crystal structure of Ng UPPS with BPH-1100 , a known phthalic acid–based UPPS inhibitor, revealing that the enzyme adopts an open, ligand-competent conformation without significant rearrangement. Our results validate Ng UPPS as a structurally tractable antibacterial target and provide a strong foundation for fragment-based optimization and the future development of novel inhibitors to combat drug-resistant N. gonorrhoeae .
- Open Access
- 22 April 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (8)
PRMT5 promotes full-length HTT expression by repressing multiple proximal intronic polyadenylation sites
Expansion of the CAG trinucleotide repeat tract in exon 1 of the Huntingtin (HTT) gene causes Huntington’s disease (HD) through the expression of a polyglutamine-expanded form of the HTT protein. This mutation triggers cellular and biochemical pathologies, leading to cognitive, motor, and psychiatric symptoms in HD patients. Targeting HTT splicing with small molecule drugs is a compelling approach to lowering HTT protein levels to treat HD, and splice modulators are currently being tested in the clinic. Here, we identify PRMT5 as a novel regulator of HTT messenger RNA (mRNA) splicing and alternative polyadenylation. PRMT5 inhibition disrupts the splicing of HTT introns 9 and 10, leading to the activation of multiple proximal intronic polyadenylation sites within these introns and promoting premature termination, cleavage, and polyadenylation of the HTT mRNA. This suggests that HTT protein levels may be lowered due to this mechanism. We also detected increasing levels of these truncated HTT transcripts across a series of neuronal differentiation samples, which correlated with lower PRMT5 expression. Notably, PRMT5 inhibition in glioblastoma stem cells potently induced neuronal differentiation. We posit that PRMT5-mediated regulation of intronic polyadenylation, premature termination, and cleavage of the HTT mRNA modulates HTT expression and plays an important role during neuronal differentiation.
- 22 April 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (8)
Open AccessPRMT5 promotes full-length HTT expression by repressing multiple proximal intronic polyadenylation sites
Expansion of the CAG trinucleotide repeat tract in exon 1 of the Huntingtin (HTT) gene causes Huntington’s disease (HD) through the expression of a polyglutamine-expanded form of the HTT protein. This mutation triggers cellular and biochemical pathologies, leading to cognitive, motor, and psychiatric symptoms in HD patients. Targeting HTT splicing with small molecule drugs is a compelling approach to lowering HTT protein levels to treat HD, and splice modulators are currently being tested in the clinic. Here, we identify PRMT5 as a novel regulator of HTT messenger RNA (mRNA) splicing and alternative polyadenylation. PRMT5 inhibition disrupts the splicing of HTT introns 9 and 10, leading to the activation of multiple proximal intronic polyadenylation sites within these introns and promoting premature termination, cleavage, and polyadenylation of the HTT mRNA. This suggests that HTT protein levels may be lowered due to this mechanism. We also detected increasing levels of these truncated HTT transcripts across a series of neuronal differentiation samples, which correlated with lower PRMT5 expression. Notably, PRMT5 inhibition in glioblastoma stem cells potently induced neuronal differentiation. We posit that PRMT5-mediated regulation of intronic polyadenylation, premature termination, and cleavage of the HTT mRNA modulates HTT expression and plays an important role during neuronal differentiation.
- Open Access
- 1 April 2025
- Published by MDPI AG in Preprints.org
Efficient Synthesis of 6-Arylaminoflavones via Buchwald-Hartwig Amination and Its Anti-Tumor Investigation
A new series of 6-arylaminoflavones was synthesized via the Buchwald-Hartwig cross-coupling reaction, aiming to functionalize the flavone core efficiently. Reaction optimization revealed that Pd₂(dba)₃/XantPhos with Cs₂CO₃ in toluene provided the best yields, with isolated yields ranging from 8% to 95%, depending on the arylamine structure. Steric hindrance and electron-withdrawing groups at the arylamine ring negatively impacted the reaction. Cytotoxicity assays indicated that specific substituents at the 6-position influenced biological activity, with trifluoromethyl- (13c) and chlorine-containing (13g) derivatives showing higher selectivity towards prostate cancer cells (PC3). These findings provide insights into the structure-activity relationship of 6-arylaminoflavones while contributing to the development of synthetic methodologies for functionalized flavones.
- 1 April 2025
- Published by MDPI AG in Preprints.org
Open AccessEfficient Synthesis of 6-Arylaminoflavones via Buchwald-Hartwig Amination and Its Anti-Tumor Investigation
A new series of 6-arylaminoflavones was synthesized via the Buchwald-Hartwig cross-coupling reaction, aiming to functionalize the flavone core efficiently. Reaction optimization revealed that Pd₂(dba)₃/XantPhos with Cs₂CO₃ in toluene provided the best yields, with isolated yields ranging from 8% to 95%, depending on the arylamine structure. Steric hindrance and electron-withdrawing groups at the arylamine ring negatively impacted the reaction. Cytotoxicity assays indicated that specific substituents at the 6-position influenced biological activity, with trifluoromethyl- (13c) and chlorine-containing (13g) derivatives showing higher selectivity towards prostate cancer cells (PC3). These findings provide insights into the structure-activity relationship of 6-arylaminoflavones while contributing to the development of synthetic methodologies for functionalized flavones.